Treatment of venous thromboembolism

Wiener Medizinische Wochenschrift

Volumn 155, Issue 1-2, 2005, Pages 7-10

  Eichinger, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Pulmonary embolism; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RAZAXABAN; RIVAROXABAN; TINZAPARIN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PROPHYLAXIS; SECONDARY PREVENTION; THROMBOSIS PREVENTION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ADMINISTRATION, ORAL; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; VENOUS THROMBOSIS; VITAMIN K;

EID: 17444414966     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-004-0140-6     Document Type: Article

References (11)

1. Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1: 1309-1312
2. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800-809
3. van den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, Burihan E (2000) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2: CD001100
4. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337: 688-698
5. Couturaud F, Julian JA, Kearon C (2001) Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost 86: 980-984
6. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64S-94S
7. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Deniers C, Kovacs M (1996) A comparison of low molecular weight heparin administered primarily at home with UFH administered in the hospital for proximal deep vein thrombosis. N Engl J Med 334: 677-681
8. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334: 682-687
9. Levine MN, Raskob G, Landefeld S, Kearon C (2001) Hemorrhagic complications of anticoagulant treatment. Chest 119: 108S-121S
10. The Columbus Investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337: 657-662
11. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mortier D, Beau B (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 337: 663-669